3-year study of tirzepatide shows that most patients only gain 5% or less from their lowest or ‘nadir’ weight
Reports and Proceedings
Updates every hour. Last Updated: 11-Sep-2025 10:11 ET (11-Sep-2025 14:11 GMT/UTC)
*Note – this is an early press release from the European Congress on Obesity in Malaga, Spain, 11-14 May. Please credit the congress when using this research.*
New research to be presented at this year’s European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that around two thirds of participants of the SURMOUNT-1 trial had only regained 5% or less of their so-called nadir (or lowest weight) three years after beginning treatment with tirzepatide. The study is by Professor Louis Aronne, Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York, NY, USA, and co-authors from Eli Lilly and Company, Indianapolis, IN, USA, which funded the study.
Researchers plan to develop flexible, neuron-like nano-devices to add energy-efficient artificial intelligence to energy-hungry applications such as battery-powered miniature drones.
A longstanding mystery in Parkinson’s disease research has been why some individuals carrying pathogenic variants that increase their risk of PD go on to develop the disease, while others who also carry such variants do not. The prevailing theory has suggested additional genetic factors may play a role.
To address this question, a new study from Northwestern Medicine used modern technology, called CRISPR interference, to systematically examine every gene in the human genome. The scientists identified a new set of genes that contribute to the risk of Parkinson’s disease, which opens the door to previously untapped drug targets for treating PD.